Literature DB >> 21736677

Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH.

J Ryan1, K Bloch, S L Archer.   

Abstract

The WHO classification of pulmonary hypertension (PH) recognises five distinct groups, all sharing a mean, resting, pulmonary artery pressure (PAP) > 25 mmHg. The aetiology of PH varies by group (1-pulmonary vascular disease, 2-high left heart filling pressures, 3-hypoxia, 4-unresolved pulmonary embolism and 5-miscellaneous). Inclusion in a group reflects shared histological, haemodynamic and pathophysiological features and has therapeutic implications. Advantages of using rodent models to understand the pathophysiology of human PH and to test experimental therapies include the economy, safety and mechanistic certainty they provide. As rodent models are meant to reflect human PH, they should be categorised by a parallel PH classification and limitations in achieving this ideal recognised. Challenges with rodent models include: accurate phenotypic characterisation (haemodynamics, histology and imaging), species and strain variations in the natural history of PH, and poor fidelity to the relevant human PH group. Rat models of group 1 PH include: monocrotaline (± pneumonectomy), chronic hypoxia + SU-5416 (a VEGF receptor inhibitor) and the fawn-hooded rat (FHR). Mouse models of group 1 PH include: transgenic mice overexpressing the serotonin transporter or dominant-negative mutants of bone morphogenetic protein receptor-2. Group 1 PH is also created by infecting S100A4/Mts1 mice with γ-herpesvirus. The histological features of group 1 PH, but not PH itself, are induced by exposure to Schistosoma mansoni or Stachybotrys chartarum. Group 3 PH is modelled by exposure of rats or mice to chronic hypoxia. Rodent models of groups 2, 4 and 5 PH are needed. Comprehensive haemodynamic, histological and molecular phenotyping, coupled with categorisation into WHO PH groups, enhances the utility of rodent models.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21736677     DOI: 10.1111/j.1742-1241.2011.02710.x

Source DB:  PubMed          Journal:  Int J Clin Pract Suppl        ISSN: 1368-504X


  32 in total

Review 1.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

Review 2.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

3.  Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.

Authors:  Ketul R Chaudhary; Yupu Deng; Colin M Suen; Mohamad Taha; Thomas H Petersen; Shirley H J Mei; Duncan J Stewart
Journal:  Br J Pharmacol       Date:  2018-09-16       Impact factor: 8.739

4.  Lung ¹⁸F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension.

Authors:  Glenn Marsboom; Christian Wietholt; Chad R Haney; Peter T Toth; John J Ryan; Erik Morrow; Thenappan Thenappan; Peter Bache-Wiig; Lin Piao; Jonathan Paul; Chin-Tu Chen; Stephen L Archer
Journal:  Am J Respir Crit Care Med       Date:  2012-01-12       Impact factor: 21.405

Review 5.  Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

Authors:  Ping Yu Xiong; Francois Potus; Winnie Chan; Stephen L Archer
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

6.  Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension.

Authors:  Lin Piao; Yong-Hu Fang; Kishan Parikh; John J Ryan; Peter T Toth; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2013-06-21       Impact factor: 4.599

7.  Targeting mitochondrial reactive oxygen species to modulate hypoxia-induced pulmonary hypertension.

Authors:  Sherry E Adesina; Bum-Yong Kang; Kaiser M Bijli; Jing Ma; Juan Cheng; Tamara C Murphy; C Michael Hart; Roy L Sutliff
Journal:  Free Radic Biol Med       Date:  2015-06-12       Impact factor: 7.376

Review 8.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

9.  FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate.

Authors:  Lin Piao; Vaninder K Sidhu; Yong-Hu Fang; John J Ryan; Kishan S Parikh; Zhigang Hong; Peter T Toth; Erik Morrow; Shelby Kutty; Gary D Lopaschuk; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2012-12-18       Impact factor: 4.599

Review 10.  A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?

Authors:  Gerald Maarman; Sandrine Lecour; Ghazwan Butrous; Friedrich Thienemann; Karen Sliwa
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.